Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 1051 to 1075 of 2013

TitleReference numberPublishedLast updated
Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinomaHTG489
Eltrombopag for treating chronic immune thrombocytopeniaTA293
Romiplostim for the treatment of chronic immune thrombocytopeniaTA221
Myeloma: diagnosis and managementNG35
Lyme diseaseNG95
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanomaTA544
Renal replacement therapy and conservative managementNG107
Decision-making and mental capacityNG108
Cabozantinib for untreated advanced renal cell carcinomaTA542
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aortaHTG326
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemiaTA541
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancerHTG487
Preventing suicide in community and custodial settingsNG105
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumoursTA539
Leadless cardiac pacemaker implantation for bradyarrhythmiasHTG484
Superior rectal artery embolisation for haemorrhoidsHTG485
Flu vaccination: increasing uptakeNG103
Dinutuximab beta for treating neuroblastomaTA538
Sutureless aortic valve replacement for aortic stenosisHTG483
Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasiaHTG482
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Community pharmacies: promoting health and wellbeingNG102

Results per page

  1. 10
  2. 25
  3. 50
  4. All